Akihiko Watanabe
Directeur/Membre du Conseil chez United Immunity Co. Ltd.
Postes actifs de Akihiko Watanabe
Sociétés | Poste | Début | Fin |
---|---|---|---|
United Immunity Co. Ltd.
United Immunity Co. Ltd. Pharmaceuticals: MajorHealth Technology United Immunity Co. Ltd. is a Japanese company that specializes in pipeline nano technology and immunity fusion technology, specifically in the field of cancer immunotherapy. The company is based in Tsu, Japan and was founded in 2017 by Naozumi Harada, who has been the CEO since then. The company's diverse products, including "nano immunotherapy," have shown promising clinical results and research in the treatment of sex cancer. The company is currently recruiting a researcher in the cancer immunotherapy field to analyze the action mechanism of nanotechnology applied cancer evaluation and drug evaluation using immunological methods. The company's focus is on the development of treatment for the cause of cold tumor type cancer through the understanding of tumor-associated macrophages. | Directeur/Membre du Conseil | - | - |
Corporate Officer/Principal | - | - |
Historique de carrière de Akihiko Watanabe
Statistiques
Internationale
Japon | 2 |
Opérationnelle
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
United Immunity Co. Ltd.
United Immunity Co. Ltd. Pharmaceuticals: MajorHealth Technology United Immunity Co. Ltd. is a Japanese company that specializes in pipeline nano technology and immunity fusion technology, specifically in the field of cancer immunotherapy. The company is based in Tsu, Japan and was founded in 2017 by Naozumi Harada, who has been the CEO since then. The company's diverse products, including "nano immunotherapy," have shown promising clinical results and research in the treatment of sex cancer. The company is currently recruiting a researcher in the cancer immunotherapy field to analyze the action mechanism of nanotechnology applied cancer evaluation and drug evaluation using immunological methods. The company's focus is on the development of treatment for the cause of cold tumor type cancer through the understanding of tumor-associated macrophages. | Health Technology |
- Bourse
- Insiders
- Akihiko Watanabe
- Expérience